The U.S. Food and Drug Administration (FDA) Monday approved the updated COVID-19 injections manufactured by Pfizer and Moderna.
These COVID-19 boosters allegedly target the latest scariant (omicron variant XBB.1.5.).
It’s impossible to keep track of all the “variants” the regulatory agencies use to frighten the public.
After getting the nod from the FDA, Pfizer and Moderna require approval from the Centers for Disease Control and Prevention (CDC) before the shots become publicly available.
The Biden administration intends to roll out the dangerous, ineffective injections by mid-September.
FDA approves updated Covid vaccines from Pfizer and Moderna https://t.co/gOmQjLL3TY
— CNBC Now (@CNBCnow) September 11, 2023
CNBC reports:
The new vaccines, which target the omicron variant XBB.1.5, are approved for people 12 and older and are authorized under emergency use for children 6 months through 11 years old, according to an FDA release.
The updated vaccines from Pfizer and Moderna won’t be available to Americans just yet.
A CDC advisory panel is scheduled to meet Tuesday to vote on a recommendation on the use of those jabs. After the CDC director signs off on those recommendations, the shots can be administered at pharmacies, health clinics and other vaccine distribution sites.
The Biden administration said last month that it expects new single-strain vaccines from Pfizer, Moderna and Novavax targeting XBB.1.5 to be available to the public in mid-September.
The FDA did not make a decision Monday on an updated Covid shot from Novavax, but the company said in a statement that the agency is still reviewing its vaccine. Shares of Novavax fell about 10% on Monday following the approval of the other updated jabs.
Novavax’s vaccine uses protein-based technology, a decades-old method deployed in routine vaccinations against hepatitis B and shingles. Meanwhile, Pfizer and Moderna’s shots use messenger RNA, which teaches cells how to make proteins that trigger an immune response against Covid.
➡️ Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine.
— U.S. FDA (@US_FDA) September 11, 2023
➡️ Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated authorized Moderna COVID-19 Vaccine.
— U.S. FDA (@US_FDA) September 11, 2023
Barring the emergence of a markedly more virulent variant, the FDA anticipates that the composition of COVID-19 vaccines may need to be updated annually, as is done for the seasonal influenza vaccine.
— U.S. FDA (@US_FDA) September 11, 2023
The updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
— U.S. FDA (@US_FDA) September 11, 2023
“The shots target XBB.1.5, a subvariant of the Omicron virus variant. That subvariant has already largely been displaced by newer strains, including EG.5, according to the U.S. Centers for Disease Control and Prevention (CDC),” Chief Nerd stated, referencing a report from The Epoch Times.
“The FDA approved the Moderna and Pfizer vaccines for people aged 12 and older. Regulators granted emergency authorization for the shots for people aged 6 months to 11 years of age.
The shots target XBB.1.5, a subvariant of the Omicron virus variant. That subvariant has already… pic.twitter.com/DrjHLla8aJ
— Chief Nerd (@TheChiefNerd) September 11, 2023
There is no “emergency.”
Yet, the Pharma-captured regulatory agency will attempt any justification to line the pockets of pharmaceutical manufacturers.
Exactly
— Chief Nerd (@TheChiefNerd) September 11, 2023
The FDA stated in its release:
Specifically, today’s actions include:
- Approval of Comirnaty (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, and a change to a single dose for individuals 12 years of age and older. Comirnaty was previously approved as a two-dose series for individuals 12 years of age and older.
- Approval of Spikevax (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, a change to a single dose for individuals 18 years of age and older, and approval of a single dose for individuals 12 through 17 years of age. Spikevax was previously approved as a two-dose series for individuals 18 years of age and older.
- Authorization of Moderna COVID-19 Vaccine for emergency use in individuals 6 months through 11 years of age to include the 2023-2024 formula and lower the age eligibility for receipt of a single dose from 6 years to 5 years of age. Additional doses are also authorized for certain immunocompromised individuals ages 6 months through 11 years, as described in the fact sheets.
- Authorization of Pfizer-BioNTech COVID-19 Vaccine for emergency use in individuals 6 months through 11 years of age to include the 2023-2024 formula. Additional doses are also authorized for certain immunocompromised individuals ages 6 months through 11 years, as described in the fact sheets.
The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was issued to Pfizer Inc.
The approval of Spikevax (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2023-2024 Formula) was issued to ModernaTX Inc.
However, not every public health official is on board with the latest COVID-19 shots.
Florida Surgeon General Dr. Joseph Ladapo said to avoid the newest mRNA injections, saying “there’s been no clinical trial showing that it is a safe product for people.”
